Quality of life issues. Potential role for an oral contraceptive containing ethinyl estradiol and drospirenone.
The new combined oral contraceptive containing ethinyl estradiol and drospirenone has the potential for improving a woman's quality of life. Drospirenone's antiandrogenic activity, for example, makes it effective in reducing acne and seborrhea. The majority of reproductive-age women suffer from some degree of premenstrual symptomatology. In some cases, these monthly symptoms are severe enough to negatively impact a woman's quality of life. Drospirenone's antimineralocorticoid activity aids in reducing some of the most bothersome symptoms associated with the premenstrual phase of the menstrual cycle.
Dickerson
Vivian
V
Department of Obstetrics and Gynecology, University of California Irvine Medical Center, 101 The City Drive, Building 53, Room 215, Orange, CA 92868, USA.
D000152:Acne Vulgaris / Q000188:drug therapy; D000726:Androgen Antagonists; D000736:Androstenes / Q000008:administration & dosage* / Q000627:therapeutic use; D003277:Contraceptives, Oral, Combined; D004997:Ethinyl Estradiol / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008901:Mineralocorticoids / Q000037:antagonists & inhibitors; D011293:Premenstrual Syndrome / Q000188:drug therapy; D045167:Progesterone Congeners / Q000008:administration & dosage* / Q000627:therapeutic use; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D015430:Weight Gain
D000726:Androgen Antagonists; D000736:Androstenes; D003277:Contraceptives, Oral, Combined; D008901:Mineralocorticoids; D045167:Progesterone Congeners; D004997:Ethinyl Estradiol; C035144:drospirenone